Rodman & Renshaw analyst Brandon Folkes initiated coverage of CorMedix with a Buy rating and $13 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- Biotech Alert: Searches spiking for these stocks today
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update
- CorMedix reports Q2 EPS (25c), consensus (25c)
- CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024
- Is CRMD a Buy, Before Earnings?